您的购物车当前为空
BAD (103-127) (human) is a 25-mer peptide obtained from the BH3 domain of BAD. It effectively counteracts the activity of Bcl-xL. Notably, BAD (103-127) (human) exhibits an approximately 800-fold greater binding affinity for Bcl-xL compared to the 16-mer peptide.

BAD (103-127) (human) is a 25-mer peptide obtained from the BH3 domain of BAD. It effectively counteracts the activity of Bcl-xL. Notably, BAD (103-127) (human) exhibits an approximately 800-fold greater binding affinity for Bcl-xL compared to the 16-mer peptide.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 100 mg | 待询 | 待询 | |
| 500 mg | 待询 | 待询 |
| 产品描述 | BAD (103-127) (human) is a 25-mer peptide obtained from the BH3 domain of BAD. It effectively counteracts the activity of Bcl-xL. Notably, BAD (103-127) (human) exhibits an approximately 800-fold greater binding affinity for Bcl-xL compared to the 16-mer peptide. |
| 分子量 | 3103.52 |
| 分子式 | C137H212N42O39S |
| CAS No. | 331762-68-6 |
| Smiles | CSCC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O |@@:170| |
| Sequence | Asn-Leu-Trp-Ala-Ala-Gln-Arg-Tyr-Gly-Arg-Glu-Leu-Arg-Arg-Met-Ser-Asp-Glu-Phe-Val-Asp-Ser-Phe-Lys-Lys |
| Sequence Short | NLWAAQRYGRELRRMSDEFVDSFKK |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多